Skip to main content

Clinical Data's Q3 Revenues up 31 Percent

This article has been updated to include additional financial information and an updated stock quote.
 
NEW YORK (GenomeWeb News) – Clinical Data today reported a 31 percent increase in third-quarter revenues, while its net loss from continuing operations more than doubled.
 
For the three months ended Dec. 31, 2007, Clinical Data brought in revenues of $10.5 million, up from $8 million in the comparable period a year ago. Sales for the firm’s PGxHealth unit rose 52 percent to $1.4 million from $939,000, while revenues for the Cogenics unit climbed 29 percent to $9.1 million from $7.1 million.
 
The Newton, Mass.-based firm posted a net loss from continuing operations of $13.9 million, or $.66 per share, compared with a net loss from continuing operations of $6.2 million, or $.43 per share, in the third quarter of 2006.
 
Including income of $9.5 million from discontinued operations, Clinical Data would have posted a net loss of $4.3 million, or $.21 per share.
 
Clinical Data’s R&D costs more than doubled year over year to $7.8 million from $3.7 million, and its SG&A costs climbed to $9.9 million from $6.1 million. The company's R&D costs for the quarter included a $3.6 million equity milestone payment to Merck KGaA related to completion of the first phase III study of its depression drug Vilazodone.
 
Clinical Data said that the drug met its primary and secondary clinical endpoints, which triggered the milestone payment. The company intends to launch a second Phase III study of the drug during its fiscal fourth quarter and expects to file for approval from the US Food and Drug Administration during 2009.
 
The firm finished the quarter with $76.9 million in cash, cash equivalents, and marketable securities.
 
Clinical Data’s shares were up 5.4 percent at $22.50 in Thursday afternoon trade on the Nasdaq.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.